IL137329A0 - Vla-4 antagonists - Google Patents

Vla-4 antagonists

Info

Publication number
IL137329A0
IL137329A0 IL13732999A IL13732999A IL137329A0 IL 137329 A0 IL137329 A0 IL 137329A0 IL 13732999 A IL13732999 A IL 13732999A IL 13732999 A IL13732999 A IL 13732999A IL 137329 A0 IL137329 A0 IL 137329A0
Authority
IL
Israel
Prior art keywords
vla
antagonists
Prior art date
Application number
IL13732999A
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL137329A0 publication Critical patent/IL137329A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13732999A 1998-01-23 1999-01-21 Vla-4 antagonists IL137329A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1233698A 1998-01-23 1998-01-23
US11072398P 1998-12-03 1998-12-03
PCT/EP1999/000384 WO1999037605A1 (en) 1998-01-23 1999-01-21 Vla-4 antagonists

Publications (1)

Publication Number Publication Date
IL137329A0 true IL137329A0 (en) 2001-07-24

Family

ID=26683440

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13732999A IL137329A0 (en) 1998-01-23 1999-01-21 Vla-4 antagonists

Country Status (13)

Country Link
EP (1) EP1049665A1 (en)
JP (1) JP4564654B2 (en)
KR (1) KR20010034317A (en)
CN (1) CN1294576A (en)
AU (1) AU746174B2 (en)
BR (1) BR9907733A (en)
CA (1) CA2318639A1 (en)
EE (1) EE200000428A (en)
HU (1) HUP0100336A3 (en)
ID (1) ID26665A (en)
IL (1) IL137329A0 (en)
NO (1) NO20003694L (en)
WO (1) WO1999037605A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043369A1 (en) * 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
IL143929A0 (en) 1999-01-22 2002-04-21 Elan Pharm Inc Acyl derivatives which treat vla-4 related disorders
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
AU3246600A (en) 1999-03-01 2000-09-21 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
AU3006401A (en) * 1999-12-07 2001-06-18 Novartis Ag Vla-4 integrin antagonists
JP2003519697A (en) 1999-12-28 2003-06-24 ファイザー・プロダクツ・インク Non-peptide VLA-4-dependent cell binding inhibitors useful for the treatment of inflammatory diseases, autoimmune diseases and respiratory diseases
DE10019755A1 (en) * 2000-04-20 2001-11-08 Bayer Ag New cyclic carboxylic acids are integrin antagonists, useful for treating inflammatory diseases, autoimmune and immune disorders, e.g. atherosclerosis, asthma and diabetes
GB2367816A (en) * 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
GB2369357A (en) * 2000-10-09 2002-05-29 Bayer Ag Aliphatic, cyclic amino carboxylic acids as integrin antagonists
GB2377933A (en) 2001-07-06 2003-01-29 Bayer Ag Succinic acid derivatives useful as integrin antagonists
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200610754A (en) * 2004-06-14 2006-04-01 Daiichi Seiyaku Co Vla-4 inhibitor
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
EP2510941A3 (en) 2007-02-20 2013-01-23 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
EP2860260A1 (en) 2008-04-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
ATE289991T1 (en) * 1997-12-23 2005-03-15 Aventis Pharma Ltd SUBSTITUTED BETA-ALANINES

Also Published As

Publication number Publication date
ID26665A (en) 2001-01-25
JP4564654B2 (en) 2010-10-20
CN1294576A (en) 2001-05-09
AU2829299A (en) 1999-08-09
HUP0100336A2 (en) 2001-07-30
AU746174B2 (en) 2002-04-18
NO20003694L (en) 2000-09-20
BR9907733A (en) 2000-10-17
JP2002501039A (en) 2002-01-15
HUP0100336A3 (en) 2002-11-28
EP1049665A1 (en) 2000-11-08
EE200000428A (en) 2001-12-17
WO1999037605A1 (en) 1999-07-29
CA2318639A1 (en) 1999-07-29
NO20003694D0 (en) 2000-07-19
KR20010034317A (en) 2001-04-25

Similar Documents

Publication Publication Date Title
PL341642A1 (en) Novel macrolydes
DE69904335D1 (en) Aminomethylcarbonsäurederivate
EP1092069A4 (en) Improved stud
HU9903216D0 (en) Substituted benzamide
GB9826359D0 (en) Novel receptors
IL137329A0 (en) Vla-4 antagonists
EP1068213A4 (en) Novel aminoorganofunctionalsiloxanes
GB9816729D0 (en) Substituted cyclohexylaminopyrimidines
HK1039937A1 (en) Substituted 3-thiocarbamoylpyrazoles
PL347397A1 (en) Substituted 3-aryl-pyrazoles
GB9810025D0 (en) Batlift
DE59900495D1 (en) Multimetalloxidmassen
DE69912430D1 (en) Hydroformylierungsreaktionen
HUP0102476A3 (en) Substituted cyclooctadepsipeptides
HK1039335A1 (en) Substituted benzoylcyclohexandiones
GB9808632D0 (en) Consapack
GB0005589D0 (en) New
GB9826962D0 (en) Fastenings
GB9901323D0 (en) Freeface 1
GB9803582D0 (en) Post-protectors
PL341899A1 (en) Vla-4 antagonists
DE59911094D1 (en) Tryptase-inhibitoren
TW407677U (en) Form
GB9816429D0 (en) Fastenings
GB9916299D0 (en) Dogex 1